Impact of Human Immunodeficiency Infection on Incidence of Autoimmmune Hemolytic Anemia (AIHA) in Patients with Hepatitis C; Correlation the Genotype of Hepatitis C Virus and AIHA

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4580-4580
Author(s):  
Yelena Patsiornik ◽  
Mushammat Nesa ◽  
Scott Foss ◽  
Michael Bernstein ◽  
Jack Burton

Abstract Background: Autoimmune hematologic abnormalities are frequent among patients with chronic hepatitis C, possibly related to the lymphotropic nature of hepatitis C virus (HCV). It is generally accepted that B-cells infected with HCV clonally expand and produce autoantibodies, which can explain the high prevalence of serological markers of autoimmunity in patients with chronic HCV infection. We recently reported significantly higher incidence of autoantibodies to RBCs and autoimmune hemolytic anemia (AIHA) in patients with HCV as compared to healthy blood donors. Human immunodeficiency virus (HIV) infection is associated with numerous hematologic manifestations. A review of current literature review indicates that a positive direct antiglobulin test (DAT) has been observed in 20% to 40% patients with clinical AIDS. Overt AIHA in patients with AIDS is rare, but can be lethal due to the lack of adequate bone marrow reserve. Many of these patients are also co-infected with HCV, which tends to make immunologic dysregulation more pronounced. Our current analysis of 68 patients, who are positive for both HIV and HCV showed a higher incidence of RBC autoantibodies and clinical AIHA, compared with patients with hepatitis C or HIV/AIDS only. We hypothesized that patients with coinfection with hepatitis C and HIV with anemia would have a higher incidence of AIHA and, thus, would benefit from DAT testing at baseline to detect potentially severe AIHA. Patients and Method: To test this hypothesis, we conducted a retrospective study to confirm that HCV infection in patients with HIV significantly increases the risk of AIHA. A group of 1056 patients with hepatitis C from our hospital’s database from July 2004 to December 2007 was studied. Of this group, 99 patients were co-infected with HCV and HIV. We also looked for an association, if any, of HCV genotype and clinically significant AIHA. Result: Our data showed that AIHA was diagnosed in 9/1056 patients with hepatitis C. Out of this group 6 (0.57%) patients had hepatitis C infection only and 3 (0.3%) patients had co-infection with HCV and HIV. The Z-test was applied to these data from the two groups (HCV+ and HCV+/HIV+) to determine if they were significantly different from one another. The Z-value was determined to be 2.064, with 1-tail confidence level of 98% and 2-tail confidence level of 96.1%, which gives a P value of 0.039 and 0.02, respectively, for the HepC/HIV co-infected group compared with the group of patients infected with HepC only. However, no association between AIHA and particular HCV genotype was noted. Conclusions: Our results indicate that patients with hepatitis C have a relatively high incidence of AIHA, which is even higher in patients concurrently infected with HIV. No particular genotype of HCV was associated with AIHA. In a view of the potential clinical severity of this condition, there needs to be a high degree of clinical suspicion for possible AIHA in patients with co-infection with hepatitis C and HIV.

2020 ◽  
Author(s):  
James A. NDAKO ◽  
Akinyomade O Owolabi ◽  
Joseph A. Olisa ◽  
Jeremiah A. Akinwumi ◽  
Victor T. Dojumo ◽  
...  

Abstract Background: Hepatitis C virus (HCV) infection and type 2 diabetes mellitus (T2DM) are two major public health problems associated with increasing complications and mortality rates worldwide. The objective of this study to evaluate the prevalence of hepatitis C virus (HCV) infection in diabetic patients and to investigate the influence of several epidemiological and clinical factors on HCV infection. Method: A total number of one hundred and eighty diabetic patients were recruited for this study. Consented subjects made up of 71(39.4%) males and 109(60.56%) females were recruited for the study. While one-Hundred (100) Non-Diabetics (Controls) were recruited for this study. Structured questionnaires were administered to the consented participants to obtain relevant data. Sera samples were assayed for antibodies to HCV using an enzyme linked immunosorbent assay [Inteco Diagnostic Limited]. ELISA technique.Result: Overall prevalence of HCV infection among diabetes patients assayed was 13.3%. Out of which 8(11.3%) was obtained from the male subjects compared to 16 (14.7%) seropositivity recorded for the female subjects (P = 0.511; P > 0.05). Considering age distribution, Subjects aged 41-50 years recorded, 9 (22.5%) positivity (P= 0.238; P>0.05).Considering educational status of subjects screened, 22 (14.9%) positivity was rescored among subjects who have attained tertiary status of education.( P = 0.574;P>0.05).Risk factors considered showed that, 7 (18.9%) seropositive subject were alcoholic consumers(P value = 0.2621;P>0.05) while 5 (8.9%) recorded history of sharing sharp objects P= 0.2427;P>0.05).Conclusion: Our study shows a slightly higher prevalence of hepatitis C infection in type 2 diabetics. This call for urgent routine screening exercise among diabetic patients for HCV infection. This study also emphasizes the need for public enlightenment on the association between HCV infection and T2DM, to avert possible complications among diabetic patients.


2014 ◽  
Vol 2 (3) ◽  
pp. 525-528 ◽  
Author(s):  
Hysaj Vila Brunilda ◽  
Shundi Lila ◽  
Abazaj Erjona ◽  
Bino Silva ◽  
Rexha Tefta

BACKGROUND: Hepatitis C is a blood-borne, infectious, viral disease that is caused by a hepatotropic virus called Hepatitis C virus (HCV).AIM: The aim of this study is to determine the prevalence of active HCV infection (HCV–RNA) in the cases that were anti-HCV positive.MATERIAL AND METHODS: Plasma of 301 high-risk for HCV infection consecutive from University Hospital Centre “Mother Theresa” Tirana-Albania, during January 2007 to December 2010 was included in this study. To identify the presence of HCV RNA, the samples were examined by Cobas Amplicor HCV test (qualitative method).RESULTS: From 301 samples analyzed in total, 214 of them resulted positive for the presence of HCV-RNA's, corresponding to a prevalence of 71.1%, with 95% CI interval [65.8 - 75.9] for value of χ2 = 52.7 p value <0.0001. Divide by the sex 56% were males and 44% females, with statistically significant difference between them for value χ2 =4306 p value=0.0380. Among the age groups the highest prevalence was observed in the age groups > 25 years with a significant difference with other age groups for p value <0.001.CONCLUSION: Among tested samples, 71.1 % were confirmed to be positive for HCV –RNA infections. The prevalence of male was highest compared to female. For males and females infected the prevalence was highest in the age group of > 25 years.


Blood ◽  
1998 ◽  
Vol 92 (9) ◽  
pp. 3486-3488 ◽  
Author(s):  
Cristian Antonescu ◽  
Claude Mayerat ◽  
Alain Mantegani ◽  
Philippe C. Frei ◽  
François Spertini ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-4
Author(s):  
Amer Awad ◽  
Olaf Stüve ◽  
Marlyn Mayo ◽  
Rafeed Alkawadri ◽  
Bachir Estephan

Extrahepatic immunological manifestations of hepatitis C virus (HCV) are well described. In addition, antiglutamic acid decarboxylase (GAD) antibody-associated cerebellar ataxia is well-established entity. However, there have been no reports in the literature of anti-GAD antibody-associated ataxia as an extrahepatic manifestation of HCV infection. We report the case of a young woman with chronic hepatitis C virus and multiple extrahepatic autoimmune diseases including Sjögren syndrome and pernicious anemia who presented with subacute midline cerebellar syndrome and was found to have positive antiglutamic acid decarboxylase (GAD) antibody in the serum and cerebrospinal fluid. An extensive diagnostic workup to rule out neoplastic growths was negative, suggesting the diagnosis of nonparaneoplastic antiglutamic acid decarboxylase antibody-associated cerebellar ataxia as an additional extrahepatic manifestation of hepatitis C virus infection. The patient failed to respond to high-dose steroids and intravenous immunoglobulin. Treatment with the monoclonal antibody rituximab stabilized the disease. We postulate that anti-GAD associated ataxia could be an extrahepatic manifestation of HCV infection.


2020 ◽  
Vol 20 (1) ◽  
Author(s):  
James A. Ndako ◽  
Akinyomade O. Owolabi ◽  
Joseph A. Olisa ◽  
Jeremiah A. Akinwumi ◽  
Victor T. Dojumo ◽  
...  

Abstract Background Hepatitis C virus (HCV) infection and type 2 diabetes mellitus (T2DM) are two major public health problems associated with increasing complications and mortality rates worldwide. The objective of this study is to evaluate the prevalence of hepatitis C virus (HCV) infection in diabetic patients and to investigate the influence of several epidemiological and clinical factors on HCV infection. Method A total number of one hundred and eighty diabetic patients were recruited for this study. Consented subjects made up of 71(39.4%) males and 109(60.56%) females were recruited for the study. While one-Hundred (100) Non-Diabetics (Controls) were also recruited for the study. Structured questionnaires were administered to the consented participants to obtain relevant data. Sera samples were assayed for antibodies to HCV using an enzyme linked immunosorbent assay [Inteco Diagnostic Limited]. ELISA technique. Result Overall prevalence of HCV infection among diabetes patients assayed was 13.3% out of which 8(11.3%) was obtained from the male subjects compared to 16 (14.7%) seropositivity recorded among the females (P = 0.511; P > 0.05). Considering age distribution, Subjects aged 41–50 years recorded, 9 (22.5%) positivity (P = 0.238; P > 0.05).Considering educational status of subjects screened, 22 (14.9%) positivity was rescored among subjects who have attained tertiary status of education.(P = 0.574;P > 0.05).Risk factors considered showed that, 7 (18.9%) seropositive subject were alcoholic consumers(P value = 0.2621;P > 0.05) while 5 (8.9%) recorded history of sharing sharp objects P = 0.2427;P > 0.05). Conclusion Our study shows a slightly higher prevalence of hepatitis C infection in type 2 diabetics. This call for urgent routine screening exercise among diabetic patients for HCV infection. This study also emphasizes the need for public enlightenment on the association between HCV infection and T2DM, to avert possible complications among diabetic patients.


PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0249585
Author(s):  
Ali Mirzazadeh ◽  
Yea-Hung Chen ◽  
Jess Lin ◽  
Katie Burk ◽  
Erin C. Wilson ◽  
...  

Background People who inject drugs (PWID) are disproportionately affected by hepatitis C virus (HCV). Data tracking the engagement of PWID in the continuum of HCV care are needed to assess the reach, target the response, and gauge impact of HCV elimination efforts. Methods We analyzed data from the National HIV Behavioral Surveillance (NHBS) surveys of PWID recruited via respondent driven sampling (RDS) in San Francisco in 2018. We calculated the number and proportion who self-reported ever: (1) tested for HCV, (2) tested positive for HCV antibody, (3) diagnosed with HCV, (4) received HCV treatment, (5) and attained sustained viral response (SVR). To assess temporal changes, we compared 2018 estimates to those from the 2015 NHBS sample. Results Of 456 PWID interviewed in 2018, 88% had previously been tested for HCV, 63% tested antibody positive, and 50% were diagnosed with HCV infection. Of those diagnosed, 42% received treatment. Eighty-one percent of those who received treatment attained SVR. In 2015 a similar proportion of PWID were tested and received an HCV diagnosis, compared to 2018. However, HCV treatment was more prevalent in the 2018 sample (19% vs. 42%, P-value 0.01). Adjusted analysis of 2018 survey data showed having no health insurance (APR 1.6, P-value 0.01) and having no usual source of health care (APR 1.5, P-value 0.01) were significantly associated with untreated HCV prevalence. Conclusion While findings indicate an improvement in HCV treatment uptake among PWID in San Francisco, more than half of PWID diagnosed with HCV infection had not received HCV treatment in 2018. Policies and interventions to increase coverage are necessary, particularly among PWID who are uninsured and outside of regular care.


2019 ◽  
Vol 72 (5) ◽  
pp. 928-932
Author(s):  
Nataliia O. Iakovenko ◽  
Maksim Y. Zak ◽  
Mykola O. Klymenko ◽  
Svetlana V. Zhuk ◽  
Olena K. Nuzhna

Introduction: Hepatitis C virus (HCV) infection is a major global problem. According to WHO, 150-200 million people globally have hepatitis C infection. Even though HCV infection morbidity rate in children is relatively low in comparison with the adult population, approximately 5 million children in the world have active HCV. There is a number of differences between HCV infection in adults and in children. However, the data pertaining to this issue is controversial. The aim: Research, analysis and synthesis of information from contemporary literature on transmission of infection and characteristics of the course of HCV infection in children. Materials and methods: Analysis and synthesis of information from contemporary literature on transmission of infection and characteristics of the course of HCV infection in children were conducted. Conclusions: Information from literature of the latest years on peculiarities of infection, disease course and complications of HCV infection in children was analyzed and summarized in this article.


Sign in / Sign up

Export Citation Format

Share Document